Systemic steroids in COPD-the beauty and the beast

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Vogelmeier, Claus F ^a,b  

^a Department of Medicine Pulmonary and Critical Care Medicine   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; PREDNISOLONE; STEROID; CORTICOSTEROID;

ARTHRALGIA; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSERVATIVE TREATMENT; DRUG EFFICACY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; HUMAN; HYPOTENSION; LUNG FUNCTION; MUSCLE STRENGTH; NOTE; PRACTICE GUIDELINE; PSYCHOSIS; RECURRENCE RISK; STEROID THERAPY; SYSTEMIC THERAPY; WEAKNESS; EVIDENCE BASED MEDICINE; FEMALE; MALE; MORTALITY;

ADRENAL CORTEX HORMONES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84899485902     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-15-38     Document Type: Note

References (17)

1. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996, 154:407-412. 10.1164/ajrccm.154.2.8756814, 8756814.
2. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999, 354:456-460. 10.1016/S0140-6736(98)11326-0, 10465169.
3. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002, 165:698-703. 10.1164/ajrccm.165.5.2109093, 11874817.
4. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003, 348:2618-2625. 10.1056/NEJMoa023161, 12826636.
5. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007, 132:1741-1747. 10.1378/chest.07-0208, 17646228.
6. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of veterans affairs cooperative study group. N Engl J Med 1999, 340:1941-1947. 10.1056/NEJM199906243402502, 10379017.
7. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, Muller B, Scherr A, Schindler C, Stoeckli R, Viatte S, von Garnier C, Tamm M, Rutishauser J. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013, 309:2223-22331. 10.1001/jama.2013.5023, 23695200.
8. Walters JA, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, 3. CD005374.
9. Renkema TE, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996, 109:1156-1162. 10.1378/chest.109.5.1156, 8625660.
10. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994, 150:11-16. 10.1164/ajrccm.150.1.8025735, 8025735.
11. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153:1958-1964. 10.1164/ajrccm.153.6.8665061, 8665061.
12. McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, Niewoehner DE. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:704-709. 10.1164/ajrccm.157.3.9703080, 9517579.
13. Horita N, Miyazawa N, Morita S, Kojima R, Inoue M, Ishigatsubo Y, Kaneko T. Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease. Resp Res 2014, 15:37.
14. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365. 10.1164/rccm.201204-0596PP, 22878278.
15. Mercadante S, Villari P, Intravaia G. Withdrawal acute psychosis after corticosteroid discontinuation. J Pain Symptom Manage 2007, 34:118-119. 10.1016/j.jpainsymman.2007.03.005, 17555921.
16. Rice KL, Rubins JB, Lebahn F, Parenti CM, Duane PG, Kuskowski M, Joseph AM, Niewoehner DE. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med 2000, 162:174-178. 10.1164/ajrccm.162.1.9909066, 10903238.
17. Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ. Severe chronic airflow obstruction: can corticosteroids slow down progression?. Eur J Respir Dis 1985, 67:56-64.